|
1
|
Raghu G, Remy-Jardin M, Richeldi L,
Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM,
Martinez FJ, et al: Idiopathic pulmonary fibrosis (an update) and
progressive pulmonary fibrosis in adults: An official
ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care
Med. 205:e18–e47. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Raghu G, Remy-Jardin M, Myers JL, Richeldi
L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F,
et al: Diagnosis of idiopathic pulmonary fibrosis. An official
ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care
Med. 198:e44–e68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Naccache JM, Jouneau S, Didier M, Borie R,
Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet
D, Prévot G, et al: Cyclophosphamide added to glucocorticoids in
acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Respir Med. 10:26–34. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fabbrizzi A, Nannini G, Lavorini F,
Tomassetti S and Amedei A: Microbiota and IPF: Hidden and detected
relationships. Sarcoidosis Vasc Diffuse Lung Dis.
38(e2021028)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Marchioni A, Tonelli R, Ball L, Fantini R,
Castaniere I, Cerri S, Luppi F, Malerba M, Pelosi P and Clini E:
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons
learned from acute respiratory distress syndrome? Crit Care.
22(80)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Juarez MM, Chan AL, Norris AG, Morrissey
BM and Albertson TE: Acute exacerbation of idiopathic pulmonary
fibrosis-a review of current and novel pharmacotherapies. J Thorac
Dis. 7:499–519. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jenkins RG, Moore BB, Chambers RC,
Eickelberg O, Königshoff M, Kolb M, Laurent GJ, Nanthakumar CB,
Olman MA, Pardo A, et al: An official american thoracic society
workshop report: Use of animal models for the preclinical
assessment of potential therapies for pulmonary fibrosis. Am J
Respir Cell Mol Biol. 56:667–679. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Khor YH: Antifibrotic therapy for
idiopathic pulmonary fibrosis: Combining real world and clinical
trials for totality of evidence. Chest. 160:1589–1591.
2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kreuter M and Maher TM: Treatment of acute
exacerbation of idiopathic pulmonary fibrosis. A call to arms. Am J
Respir Crit Care Med. 201:1030–1032. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Collard HR, Ryerson CJ, Corte TJ, Jenkins
G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM,
et al: Acute exacerbation of idiopathic pulmonary fibrosis. An
international working group report. Am J Respir Crit Care Med.
194:265–275. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kreuter M, Polke M, Walsh SLF, Krisam J,
Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T, et
al: Acute exacerbation of idiopathic pulmonary fibrosis:
International survey and call for harmonisation. Eur Respir J.
55(1901760)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
McElroy AN, Invernizzi R, Laskowska JW,
O'Neill A, Doroudian M, Moghoofei M, Mostafaei S, Li F, Przybylski
AA, O'Dwyer DN, et al: Candidate role for Toll-like receptor 3
L412F polymorphism and infection in acute exacerbation of
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
205:550–562. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji
W, Cookson WO, Moffatt MF, Kim DS and Maher TM: Changes in the
respiratory microbiome during acute exacerbations of idiopathic
pulmonary fibrosis. Respir Res. 18(29)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Stoolman JS, Vannella KM, Coomes SM, Wilke
CA, Sisson TH, Toews GB and Moore BB: Latent infection by
γherpesvirus stimulates profibrotic mediator release from multiple
cell types. Am J Physiol Lung Cell Mol Physiol. 300:L274–L285.
2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ghincea A, Ryu C and Herzog EL: An acute
exacerbation of idiopathic pulmonary fibrosis after BNT162b2 mRNA
COVID-19 vaccination: A case report. Chest. 161:e71–e73.
2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bando T, Takei R, Mutoh Y, Sasano H,
Yamano Y, Yokoyama T, Matsuda T, Kataoka K, Kimura T and Kondoh Y:
Acute exacerbation of idiopathic pulmonary fibrosis after
SARS-CoV-2 vaccination. Eur Respir J. 59(2102806)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ye X, Zhang M, Gu H, Liu M, Zhao Y, Shi Y,
Wu S, Jiang C, Ye X, Zhu H, et al: Animal models of acute
exacerbation of pulmonary fibrosis. Respir Res.
24(296)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
D'Alessandro-Gabazza CN, Yasuma T,
Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, Hataji O, Nakahara
H, Takeshita A, Nishihama K, et al: Inhibition of lung
microbiota-derived proapoptotic peptides ameliorates acute
exacerbation of pulmonary fibrosis. Nat Commun.
13(1558)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cho SJ, Moon JS, Nikahira K, Yun HS,
Harris R, Hong KS, Huang H, Choi AMK and Stout-Delgado H:
GLUT1-dependent glycolysis regulates exacerbation of fibrosis via
AIM2 inflammasome activation. Thorax. 75:227–236. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liang J, Zhang Y, Xie T, Liu N, Chen H,
Geng Y, Kurkciyan A, Mena JM, Stripp BR, Jiang D and Noble PW:
Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar
progenitor cell renewal and prevent severe pulmonary fibrosis in
mice. Nat Med. 22:1285–1293. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xie T, Liang J, Stripp B and Noble PW:
Cell-cell interactions and communication dynamics in lung fibrosis.
Chin Med J Pulm Crit Care Med. 2:63–71. 2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huang G, Geng Y, Kulur V, Liu N, Liu X,
Taghavifar F, Liang J, Noble PW and Jiang D: Arrestin beta 1
regulates alveolar progenitor renewal and lung fibrosis. J Respir
Biol Transl Med. 1(10006)2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ashley SL, Jegal Y, Moore TA, van Dyk LF,
Laouar Y and Moore BB: γ-Herpes virus-68, but not Pseudomonas
aeruginosa or influenza A (H1N1), exacerbates established murine
lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 307:L219–L230.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kim MS, Kim SH, Jeon D, Kim HY, Han JY,
Kim B and Lee K: Low-dose cadmium exposure exacerbates
polyhexamethylene guanidine-induced lung fibrosis in mice. J
Toxicol Environ Health A. 81:384–396. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
D'Alessandro-Gabazza CN, Kobayashi T,
Yasuma T, Toda M, Kim H, Fujimoto H, Hataji O, Takeshita A,
Nishihama K, Okano T, et al: A Staphylococcus pro-apoptotic peptide
induces acute exacerbation of pulmonary fibrosis. Nat Commun.
11(1539)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yang L, Lin Z, Wang Y, Li C, Xu W, Li Q,
Yao W, Song Z and Liu G: Nickle(II) ions exacerbate
bleomycin-induced pulmonary inflammation and fibrosis by activating
the ROS/Akt signaling pathway. Environ Sci Pollut Res Int.
25:4406–4418. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen S, Zhang X, Yang C, Wang S and Shen
H: Essential role of IL-17 in acute exacerbation of pulmonary
fibrosis induced by non-typeable Haemophilus influenzae.
Theranostics. 12:5125–5137. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kimura T, Nojiri T, Hosoda H, Shintani Y,
Inoue M, Miyazato M, Okumura M and Kangawa K: Exacerbation of
bleomycin-induced injury by lipopolysaccharide in mice:
Establishment of a mouse model for acute exacerbation of
interstitial lung diseases. Eur J Cardiothorac Surg. 48:e85–e91.
2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wei YR, Qiu H, Wu Q, Du YK, Yin ZF, Chen
SS, Jin YP, Zhao MM, Wang C, Weng D and Li HP: Establishment of the
mouse model of acute exacerbation of idiopathic pulmonary fibrosis.
Exp Lung Res. 42:75–86. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jia K, Wu J, Li Y, Liu J, Liu R, Cai Y,
Zhang Y and Li X: A novel pulmonary fibrosis murine model with
immune-related liver injury. Animal Model Exp Med. 6:274–282.
2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
McMillan TR, Moore BB, Weinberg JB,
Vannella KM, Fields WB, Christensen PJ, van Dyk LF and Toews GB:
Exacerbation of established pulmonary fibrosis in a murine model by
gammaherpesvirus. Am J Respir Crit Care Med. 177:771–780.
2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hübner RH, Gitter W, El Mokhtari NE,
Mathiak M, Both M, Bolte H, Freitag-Wolf S and Bewig B:
Standardized quantification of pulmonary fibrosis in histological
samples. Biotechniques. 44:507–511, 514-517. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Müller NL, Mawson JB, Mathieson JR, Abboud
R, Ostrow DN and Champion P: Sarcoidosis: Correlation of extent of
disease at CT with clinical, functional, and radiographic findings.
Radiology. 171:613–618. 1989.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Konishi K, Gibson KF, Lindell KO, Richards
TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, et
al: Gene expression profiles of acute exacerbations of idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med. 180:167–175.
2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Biondini D, Balestro E, Sverzellati N,
Cocconcelli E, Bernardinello N, Ryerson CJ and Spagnolo P: Acute
exacerbations of idiopathic pulmonary fibrosis (AE-IPF): An
overview of current and future therapeutic strategies. Expert Rev
Respir Med. 14:405–414. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Weng D, Chen XQ, Qiu H, Zhang Y, Li QH,
Zhao MM, Wu Q, Chen T, Hu Y, Wang LS, et al: The role of infection
in acute exacerbation of idiopathic pulmonary fibrosis. Mediators
Inflamm. 2019(5160694)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
O'Dwyer DN, Ashley SL, Gurczynski SJ, Xia
M, Wilke C, Falkowski NR, Norman KC, Arnold KB, Huffnagle GB,
Salisbury ML, et al: Lung microbiota contribute to pulmonary
inflammation and disease progression in pulmonary fibrosis. Am J
Respir Crit Care Med. 199:1127–1138. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Redente EF, Black BP, Backos DS, Bahadur
AN, Humphries SM, Lynch DA, Tuder RM, Zemans RL and Riches DWH:
Persistent, progressive pulmonary fibrosis and epithelial
remodeling in mice. Am J Respir Cell Mol Biol. 64:669–676.
2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhao S, Wu X, Tan Z, Li L, Ou J, Lin Y,
Song H, Feng L, Seto D, Wu J, et al: Generation of human embryonic
stem cell-derived lung organoids for modeling infection and
replication differences between human adenovirus types 3 and 55 and
evaluating potential antiviral drugs. J Virol.
97(e0020923)2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lynch JP and Kajon AE: Adenovirus:
Epidemiology, global spread of novel types, and approach to
treatment. Semin Respir Crit Care Med. 42:800–821. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Huang WJ and Tang XX: Virus infection
induced pulmonary fibrosis. J Transl Med. 19(496)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhou Y, Jin T, Gao M, Luo Z, Mutahir S,
Shi C, Xie T, Lin L, Xu J, Liao Y, et al: Aqueous extract of
Platycodon grandiflorus attenuates lipopolysaccharide-induced
apoptosis and inflammatory cell infiltration in mouse lungs by
inhibiting PI3K/Akt signaling. Chin Med. 18(36)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Li J, Lu K, Sun F, Tan S, Zhang X, Sheng
W, Hao W, Liu M, Lv W and Han W: Panaxydol attenuates ferroptosis
against LPS-induced acute lung injury in mice by Keap1-Nrf2/HO-1
pathway. J Transl Med. 19(96)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
D'Alessio FR: Mouse models of acute lung
injury and ARDS. In: Alper S, Janssen W (eds), Lung Innate Immunity
and Inflammation. Methods in Molecular Biology, vol 1809. Humana
Press, New York, NY, pp341-350, 2018.
|
|
46
|
Seemann S, Zohles F and Lupp A:
Comprehensive comparison of three different animal models for
systemic inflammation. J Biomed Sci. 24(60)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Guo B, Liu W, Ji X, Xi B, Meng X, Xie W,
Sun Y, Zhang M, Liu P, Zhang W, et al: CSF3 aggravates acute
exacerbation of pulmonary fibrosis by disrupting alveolar
epithelial barrier integrity. Int Immunopharmacol.
135(112322)2024.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pitre T, Lupas D, Ebeido I, Colak A, Modi
M, Kachkovski GV, Montesi SB, Khor YH, Kawano-Dourado L, Jenkins G,
et al: Prognostic factors associated with mortality in acute
exacerbations of idiopathic pulmonary fibrosis: A systematic review
and meta-analysis. Respir Med. 222(107515)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Moghoofei M, Mostafaei S, Kondori N,
Armstrong ME and Babaei F: Bacterial and viral coinfection in
idiopathic pulmonary fibrosis patients: The prevalence and possible
role in disease progression. BMC Pulm Med. 22(60)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yegen CH, Haine L, Da Costa Ferreira K,
Marchant D, Bernaudin JF, Planès C, Voituron N and Boncoeur E: A
new model of acute exacerbation of experimental pulmonary fibrosis
in mice. Cells. 11(3379)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Fikry H, Saleh LA and Gawad SA:
Therapeutic effect of adipose-derived mesenchymal stem cells
(AD-MSCs) compared to pirfenidone on corticosteroid resistance in a
mouse model of acute exacerbation of idiopathic pulmonary fibrosis.
Histol Histopathol. 37:1065–1083. 2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Emura I and Usuda H: Acute exacerbation of
IPF has systemic consequences with multiple organ injury, with
SRA+ and TNF-α+ cells in the systemic
circulation playing central roles in multiple organ injury. BMC
Pulm Med. 16(138)2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Papiris SA, Tomos IP, Karakatsani A,
Spathis A, Korbila I, Analitis A, Kolilekas L, Kagouridis K,
Loukides S, Karakitsos P and Manali ED: High levels of IL-6 and
IL-8 characterize early-on idiopathic pulmonary fibrosis acute
exacerbations. Cytokine. 102:168–172. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Li X, Zhou Y, Zou R, Chen H, Liu X, Qiu X,
Xiao Y, Cai H and Dai J: Associations of serological biomarkers of
sICAM-1, IL-1β, MIF, and su-PAR with 3-month mortality in acute
exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm.
2020(4534272)2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tomos I, Dimakopoulou K, Manali ED,
Papiris SA and Karakatsani A: Long-term personal air pollution
exposure and risk for acute exacerbation of idiopathic pulmonary
fibrosis. Environ Health. 20(99)2021.PubMed/NCBI View Article : Google Scholar
|
